Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px
Document › Details

Genenta Science S.r.l.. (1/19/17). "Press Release: Carlo Russo, M.D., Joins Genenta Science as Chief Medical Officer". Milan.

Organisations Organisation Genenta Science S.r.l.
  Organisation 2 Adverum Biotechnologies Inc. (Nasdaq: ADVM)
  Group Adverum Biotechnologies (Group)
Products Product gene therapy
  Product 2 clinical research
Index term Index term GSK–San Raffaele: gene therapy, 201505 collab existent gene therapy for rare diseases with Telethon + OSRI
Persons Person Russo, Carlo (Genenta Science 201701– before Adverum Biotechnologies + GSK + Vaxinnate + Merck US)
  Person 2 Paracchi, Pierluigi (Genenta Science Srl 201709 CEO + Co-Founder)
     


Genenta Science, a biotech company focused on hematopoietic stem cell gene therapy for tumor treatment, today announced that Carlo Russo, M.D. is joining the company as Chief Medical Officer.

Dr. Russo comes to Genenta from Adverum Biotechnologies, where he served as Chief Medical Officer. Previously, Dr. Russo held Senior Vice President roles at GSK, including: Founder and Manager of the Alternative Development Program, Head of the Cardiovascular and Metabolic Development Center, Founder and Head of Development of the Biopharm Unit, and most recently the Head of R&D for the Rare Disease Unit. Prior to joining GSK, Dr. Russo was the President & CEO of Vaxinnate, a vaccine biotech startup, and before that he held senior roles in the Regulatory Department of Merck Vaccine & Biologics.

Dr. Russo earned his doctorate degree in Medicine and Board Certification in Hematology at the University of Genoa Medical School. Dr. Russo’s academic appointments include: A Postdoctoral fellowship at the Scripps Research Institute in La Jolla, California, assistant professorship at the Columbia University, College Physicians and Surgeons, and Associate Professorship at the Cornell University Medical and Graduate Schools.

“Carlo has worked together with Prof. Luigi Naldini, Genenta’s co-founder, and with the clinical team of San Raffaele Hospital (OSR) along the GSK SR-TIGET Alliance on rare diseases. And contributed to the marketing authorization of the first ever ex-vivo gene therapy” said Pierluigi Paracchi, Chairman and Chief Executive Officer. “We see a great scientific and clinical potential in this reunion, we see the opportunity to reach the same outstanding results”.

“I am delighted to join Genenta Science” said Dr. Russo. “It is an exciting and unique opportunity to contribute to the development of novel gene therapy products for patients with significant unmet medical need”.


About Genenta Science

Genenta – gene therapy for tumor treatment, www.genenta.com – develops a gene transfer strategy into autologous hematopoietic stem cells (HSCs) to target specific anti-tumor proteins to tumor-infiltrating monocytes/macrophages. An HIV-derived and genetically disabled viral vector – Lentivirus – delivers the gene into the HSCs. Founders: Pierluigi Paracchi, Ospedale San Raffaele, prof. Luigi Naldini (Director SR-TIGET San Raffaele Telethon Institute for Gene Therapy) and Bernhard Gentner (Hematologist and Physician Scientist at OSR and SR-TIGET). In March 2015, Genenta Science banked 10 million Euro (USD 11 million) Series A round. And in September 2016, Genenta partnered with Amgen (Nasdaq: AMGN).


Pierluigi Paracchi, Chairman and CEO
+39 335.73.51.868
pierluigi.paracchi@genenta.com
GENENTA SCIENCE SRL
Via Olgettina, 58 - 20132 Milan (Italy)

   
Record changed: 2019-09-14

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Genenta Science S.r.l.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top